Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands-0

<p><b>Copyright information:</b></p><p>Taken from "Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands"</p><p>http://www.resource-allocation.com/content/5/1/15</p><p>Cost effectiveness and resource allocation : C/E 2007;5():15-15.</p><p>Published online 22 Nov 2007</p><p>PMCID:PMC2211743.</p><p></p>se-case value were evaluated and these values are shown on both sides of the bars. All parameters refer to costs and are expressed in Euro price level 2006. TPV/r tipranavir with ritonavir. CPI/r comparator protease inhibitor with ritonavir. HAART highly active antiretroviral therapy. iCER incremental cost effectiveness ratio. QALY quality adjusted life year